Privately held Excaliard Pharmaceuticals Inc., which started out the year by reporting positive Phase II data for its lead anti-scarring compound, EXC 001, is ending 2011 with an acquisition by pharma giant Pfizer Inc. Read More
LONDON – Europe's pharmaceutical companies have thrown their weight behind a European Commission action plan to pool efforts in the fight against antibiotic-resistant infections, and are demanding higher prices for their drugs in return for this support. Read More
Recombinant proteins are some of the biggest blockbusters around. They are anything but trivial to produce, as issues from shortages to tainted heparin have shown over the past few years. Read More
ChanRx Corp., launched in 2006 as a spinoff from Cleveland-based pharmaceutical testing company ChanTest Corp., closed a Series A financing with investments from Sante Ventures, of Austin, Texas, and company founder and chairman Arthur "Buzz" Brown. Read More
BioWorld's offices will be closed Thursday, Nov. 24, and Friday, Nov. 25, in observance of the Thanksgiving Day holiday in the U.S. No issues will be published those days. Read More
Advanced Cell Technology Inc. (ACT) is about to deliver good news from its Phase I/II trials of retinal pigmented epithelial (RPE) cells and perk up the prospects for human embryonic stem cell (hESC)-based therapies following Geron Inc.'s abrupt withdrawal from the field last week. Read More
• MabCure Inc., of New York, said it signed a license agreement with Biotech Investment Corp., a Nevada-based biotech investment company, for exclusive, worldwide rights to certain MabCure hybridoma clones producing antibodies against prostate cancer. Read More
• Peregrine Pharmaceuticals Inc., of Tustin, Calif., reported a 23.2-month median overall survival (OS) from a single-arm Phase II trial evaluating bavituximab in combination with carboplatin and paclitaxel in patients with locally advanced or metastatic breast cancer. Read More
